N@N

XenoPort Announces Pricing of Public Offering of Common Stock

^{Published on 2010-12-08 23:40:45 - Market Wire}
 

SANTA CLARA, Calif.--([ BUSINESS WIRE ])--XenoPort, Inc. (Nasdaq: XNPT) announced today the pricing of an underwritten offering of 4,000,000 shares of its common stock at a price to the public of $7.15 per share. XenoPort has granted to the underwriters a 30-day option to purchase up to an aggregate of 600,000 additional shares of common stock to cover over-allotments, if any. All of the shares in the offering are being offered by XenoPort. Morgan Stanley & Co. Incorporated is acting as bookrunner for the offering. RBC Capital Markets, LLC and Wedbush PacGrow Life Sciences are acting as co-managers.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state in which such offer, solicitation or sale is not permitted. Copies of the final prospectus supplement and accompanying prospectus may be obtained from Morgan Stanley & Co. Incorporated, Attn: Prospectus Department, 180 Varick Street, New York, New York 10014 (Email: [ prospectus@morganstanley.com ]), or by calling (866) 718-1649.

About XenoPort

XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the bodya™s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort is developing its lead product candidate in collaboration with Astellas Pharma Inc. and GlaxoSmithKline. XenoPorta™s product candidates are being studied for the potential treatment of restless legs syndrome, gastroesophageal reflux disease, neuropathic pain, spasticity and Parkinsona™s disease.

XenoPort is a registered trademark of XenoPort, Inc.

Source code: XNPT2F